Radius Health Inc
NASDAQ:RDUS

Watchlist Manager
Radius Health Inc Logo
Radius Health Inc
NASDAQ:RDUS
Watchlist
Price: 30 USD Market Closed
Market Cap: 847.8m USD

Net Margin

-3.7%
Current
Improving
by 0.9%
vs 3-y average of -4.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3.7%
=
Net Income
$-103.2m
/
Revenue
$2.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3.7%
=
Net Income
$-103.2m
/
Revenue
$2.8B

Peer Comparison

Country Company Market Cap Net
Margin
US
Radius Health Inc
NASDAQ:RDUS
847.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
36th
Based on 15 072 companies
36th percentile
-3.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Radius Health Inc
Glance View

Market Cap
847.8m USD
Industry
Biotechnology

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

RDUS Intrinsic Value
78.57 USD
Undervaluation 62%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-3.7%
=
Net Income
$-103.2m
/
Revenue
$2.8B
What is Radius Health Inc's current Net Margin?

The current Net Margin for Radius Health Inc is -3.7%, which is above its 3-year median of -4.6%.

How has Net Margin changed over time?

Over the last 3 years, Radius Health Inc’s Net Margin has decreased from 5.9% to -3.7%. During this period, it reached a low of -10.5% on Nov 30, 2024 and a high of 5.9% on May 1, 2022.

Back to Top